Sugi Predict

Sugi Predict / Compounds / SCHEMBL126301

SCHEMBL126301

SCHEMBL126301

COc1ccc(Oc2ccc(OC)c(OC)c2)cc1OC

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 3/20 0.76
▸ CA12 O43570 2/20 0.76
▸ CA1 P00915 2/20 0.76
▸ CA7 P43166 2/20 0.76
▸ CA9 Q16790 2/20 0.76
▸ CA14 Q9ULX7 2/20 0.76
▸ TUBB4A P04350 2/20 0.57
▸ TUBB P07437 2/20 0.57
▸ TUBA3C P0DPH7 2/20 0.57
▸ TUBA1B P68363 2/20 0.57
▸ TUBA4A P68366 2/20 0.57
▸ TUBB4B P68371 2/20 0.57
▸ TUBB3 Q13509 2/20 0.57
▸ TUBB2A Q13885 2/20 0.57
▸ TUBB8 Q3ZCM7 2/20 0.57
▸ TUBA3E Q6PEY2 2/20 0.57
▸ TUBA1A Q71U36 2/20 0.57
▸ TUBA1C Q9BQE3 2/20 0.57
▸ TUBB6 Q9BUF5 2/20 0.57
▸ TUBB2B Q9BVA1 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8736425 0.89 AR (0.64) CA2CA12CA1CA7CA9
SCHEMBL11646840 0.89 LTA4H (0.61) CA2CA12CA1CA7CA9
SCHEMBL13564395 0.87 CA12 (0.59) CA2CA12CA1CA7CA9
SCHEMBL177818 0.87 SMN1; SMN2 (0.61) CA2CA12CA1CA7CA9
SCHEMBL2091306 0.87 CA2 (0.59) CA2CA12CA1CA7CA9
1,2,4-Trimethoxybenzene SCHEMBL27777905 0.86 CA12 (1.00) CA2CA12CA1CA7CA9
1,2,4-Trimethoxybenzene SCHEMBL481491 0.86 CA12 (1.00) CA2CA12CA1CA7CA9
1,2,4-Trimethoxybenzene SCHEMBL29350371 0.86 CA12 (1.00) CA2CA12CA1CA7CA9
SCHEMBL7455927 0.86 CA12 (0.64) CA2CA12CA1CA7CA9
SCHEMBL2753736 0.85 CA2 (0.57) CA2CA12CA1CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105670181-A Radiation-resistant and folding-resistant cable and preparation method thereof 苏州科茂电子材料科技有限公司 2016-06-15 — — CN claimed
CN-105623035-A Marine cable material and preparing method thereof SUZHOU KEMAO ELECTRONIC MAT TECH CO LTD 2016-06-01 — — CN claimed
US-8658706-B2 Organic superacid monomers containing a bis-sulfonic acid group and methods of making and using the same GM Global Technology Operations LLC (US) 2014-02-25 — — US claimed
US-20120277332-A1 ORGANIC SUPERACID MONOMERS CONTAINING A BIS-SULFONIC ACID GROUP AND METHODS OF MAKING AND USING THE SAME GM Global Technology Operations LLC (US) 2012-11-01 — — US claimed
US-11382884-B2 Method for reducing lung infection Respirion Pharmaceuticals Pty Ltd (CA) 2022-07-12 — — US disclosed
EP-3641750-A1 METHOD FOR REDUCING LUNG INFECTION Respirion Pharmaceuticals Pty Ltd (AU) 2020-04-29 — — EP disclosed
CN-111065386-A Methods of reducing pulmonary infection 瑞斯普瑞恩制药私人有限公司 2020-04-24 — — CN disclosed
US-20200108033-A1 METHOD FOR REDUCING LUNG INFECTION Respirion Pharmaceuticals Pty Ltd (AU) 2020-04-09 — — US disclosed
US-10561649-B2 Pharmaceutical combination of opioid and prostaglandin compound SUCAMPO AG (CH) 2020-02-18 — — US disclosed
WO-2018232453-A1 METHOD FOR REDUCING LUNG INFECTION Respirion Pharmaceuticals Pty Ltd (AU) 2018-12-27 — — WO disclosed
US-20180311233-A1 PHARMACEUTICAL COMBINATION OF OPIOID AND PROSTAGLANDIN COMPOUND SUCAMPO AG (CH) 2018-11-01 — — US disclosed
CN-107903173-A Treat schizoid method 苏坎波公司 2018-04-13 — — CN disclosed
WO-2001076593-A2 BILE SECRETION PROMOTING COMPOSITION A 15-KETO PROSTAGLANDIN SUCAMPO AG (CH) 2001-10-18 — — WO disclosed
WO-2001070233-A2 APOPTOSIS INHIBITING COMPOSITION COMPRISING A 15-KETO-PROSTAGLANDIN OR DERIVATIVE THEREOF SUCAMPO AG (CH) 2001-09-27 — — WO disclosed
WO-2001068072-A2 COMPOSITION FOR USE IN TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA SUCAMPO AG (CH) 2001-09-20 — — WO disclosed
US-6245746-B1 ADMINISTERING AMIDE MICROBIOCIDE ANTIBIOTIC MICROCIDE PHARMACEUTICALS, INC. 2001-06-12 — — US disclosed
JP-2001031550-A VERATRYL ETHER DERIVATIVE KAO CORP 2001-02-06 — — JP disclosed
JP-2001031550-A VERATRYL ETHER DERIVATIVE KAO CORP 2001-02-06 — — JP disclosed
WO-2001005388-A2 USE OF A FATTY DERIVATIVE FOR THE TREATMENT OF EXTERNAL SECRETIONDISORDERS SUCAMPO, A.G. (CH) 2001-01-25 — — WO disclosed
WO-1999037667-A1 EFFLUX PUMP INHIBITORS MICROCIDE PHARMACEUTICALS, INC. (US) 1999-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277332-A1 ORGANIC SUPERACID MONOMERS CONTAINING A BIS-SULFONIC ACID GROUP AND METHODS OF MAKING AND USING THE SAME FHIT, ALAD, CA6 CA2 7/4885CA12 62/4885CA1 10/4885
US-20180311233-A1 PHARMACEUTICAL COMBINATION OF OPIOID AND PROSTAGLANDIN COMPOUND OPRK1, OPRM1, OPRD1 CA2 3214/4885CA12 3066/4885CA1 4028/4885
US-10561649-B2 Pharmaceutical combination of opioid and prostaglandin compound OPRK1, OPRM1, OPRD1 CA2 3214/4885CA12 3066/4885CA1 4028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.